Easy Multiplicity Control in Equivalence Testing Using Two One-Sided Tests

The use of equivalence testing in scientific research is increasing beyond its traditional role in the drug approval process. Largely due to its ease of use and recommendations from the U.S. Food and Drug Administration guidance, the most common statistical method for testing equivalence is the two one-sided tests (TOST) procedure. Like classical point-null hypothesis testing, TOST is subject to multiplicity concerns as more comparisons are made. Here we give a condition that bounds the familywise error rate (FWER) using TOST and leads to a simple solution for controlling the FWER. Specifically, we demonstrate that if all pairwise comparisons of k independent groups are being evaluated for equivalence, then simply scaling the nominal type I error rate down by (k−1) is sufficient to maintain the FWER at the desired value or less. The resulting rule is much less conservative than the equally simple Bonferroni correction. An example of equivalence testing in a non-drug development setting is given.

[1]  E. Lehmann Testing Statistical Hypotheses , 1960 .

[2]  W. Westlake,et al.  Symmetrical confidence intervals for bioequivalence trials. , 1976, Biometrics.

[3]  A. Dempster,et al.  A Bayesian approach to bioequivalence for the 2 x 2 changeover design. , 1981, Biometrics.

[4]  Walter W. Hauck,et al.  A new procedure for testing equivalence in comparative bioavailability and other clinical trials , 1983 .

[5]  H Fluehler,et al.  Bayesian approach to bioequivalence assessment: an example. , 1983, Journal of pharmaceutical sciences.

[6]  M. Selwyn,et al.  On Bayesian methods for bioequivalence. , 1984, Biometrics.

[7]  Eve Bofinger,et al.  Multiple Comparisons and Type III Errors , 1985 .

[8]  H. Finner,et al.  Some general results on least favorable parameter configurations with special reference to equivalence testing and the range statistic , 1991 .

[9]  S. Goodman,et al.  The Use of Predicted Confidence Intervals When Planning Experiments and the Misuse of Power When Interpreting Results , 1994, Annals of Internal Medicine.

[10]  Klaus Straßburger,et al.  Testing and Selecting for Equivalence with Respect to a Control , 1994 .

[11]  Stephen J. Ruberg,et al.  Confidence intervals associated with tests for bioequivalence , 1994 .

[12]  L. Brown,et al.  Optimal Confidence Sets, Bioequivalence, and the Limaçon of Pascal , 1995 .

[13]  R. Berger,et al.  Bioequivalence trials, intersection-union tests and equivalence confidence sets , 1996 .

[14]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[15]  J. Hsu Multiple Comparisons: Theory and Methods , 1996 .

[16]  K. Strassburger,et al.  Multiple comparison procedures for optimally discriminating between good, equivalent, and bad treatments with respect to a control , 2000 .

[17]  J. Hoenig,et al.  Statistical Practice The Abuse of Power: The Pervasive Fallacy of Power Calculations for Data Analysis , 2001 .

[18]  L. Barker,et al.  Assessing equivalence: an alternative to the use of difference tests for measuring disparities in vaccination coverage. , 2002, American journal of epidemiology.

[19]  Optimal confidence sets for testing average bioequivalence , 2002 .

[20]  William H. Press,et al.  Numerical recipes in C , 2002 .

[21]  Nicole A. Lazar,et al.  Testing Statistical Hypotheses of Equivalence , 2003, Technometrics.

[22]  R J Tempelman,et al.  Experimental design and statistical methods for classical and bioequivalence hypothesis testing with an application to dairy nutrition studies. , 2004, Journal of animal science.

[23]  Donald J. Schuirmann A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[24]  Walter W. Hauck,et al.  A new statistical procedure for testing equivalence in two-group comparative bioavailability trials , 1984, Journal of Pharmacokinetics and Biopharmaceutics.

[25]  D. Kraitchman,et al.  Radiopaque alginate microcapsules for X-ray visualization and immunoprotection of cellular therapeutics. , 2006, Molecular pharmaceutics.

[26]  Matthias Stuber,et al.  Magnetic resonance–guided, real-time targeted delivery and imaging of magnetocapsules immunoprotecting pancreatic islet cells , 2007, Nature Medicine.

[27]  B. Caffo,et al.  A survey of the likelihood approach to bioequivalence trials , 2008, Statistics in medicine.